Efficacy and safety of atezolizumab–bevacizumab vs pembrolizumab-lenvatinib in unresectable hepatocellular carcinoma: a retrospective, cohort study
This study suggests that the efficacy of pembrolizumab-lenvatinib and atezolizumab-bevacizumab is comparable in first-line treatment of unresectable HCC, the atezolizumab-bevacizumab combination may confer additional benefits for patients with high CPA scores compared to pembrolizumab-lenvatinib.
Authors
- Yizhen Fu (ORCID: https://orcid.org/0000-0003-1919-7176)
- Yaojun Zhang (ORCID: https://orcid.org/0000-0002-9752-4729)
- Zili Hu (ORCID: https://orcid.org/0000-0002-1987-730X)
- Zeliang Ma (ORCID: https://orcid.org/0000-0001-8250-0540)
- Zhuan Fu (ORCID: https://orcid.org/0000-0002-1662-047X)
- Zhongguo Zhou (ORCID: https://orcid.org/0000-0002-1929-4278)
- Zhoutian Yang (ORCID: https://orcid.org/0009-0007-0261-8479)
- Minshan Chen (ORCID: https://orcid.org/0000-0002-6116-5015)
Institutions
- Sun Yat-sen University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- The First Affiliated Hospital, Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2024-11-19
- DOI
- https://doi.org/10.3389/fimmu.2024.1472870
- Citations
- 3
- Primary Topic
- Hepatocellular Carcinoma Treatment and Prognosis
- Type
- article
- Field-Weighted Citation Impact
- 1.11